4-phenylbutyric acid and minocycline

4-phenylbutyric acid has been researched along with minocycline in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Kasetti, RB; Kodati, B; Maddineni, P; Yacoub, S; Zode, GS	1

Reviews

1 review(s) available for 4-phenylbutyric acid and minocycline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

1 other study(ies) available for 4-phenylbutyric acid and minocycline

Article	Year
Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9. International journal of molecular sciences, 2021, Sep-18, Volume: 22, Issue:18 Topics: Animals; Aqueous Humor; Cornea; Endoplasmic Reticulum Stress; Enzyme Activation; Extracellular Matrix; Eye Diseases; Fibronectins; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Ocular Hypertension; Phenylbutyrates; Sodium; Trabecular Meshwork	2021

Article

Year

Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9.

International journal of molecular sciences, 2021, Sep-18, Volume: 22, Issue:18

Topics: Animals; Aqueous Humor; Cornea; Endoplasmic Reticulum Stress; Enzyme Activation; Extracellular Matrix; Eye Diseases; Fibronectins; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Ocular Hypertension; Phenylbutyrates; Sodium; Trabecular Meshwork

2021